|
Dr. DiMarchi is the Linda & Jack Gill Chair in Biomolecular Sciences and Professor of Chemistry at Indiana University. He is a retired Group Vice President at Eli Lilly & Company where for more than two decades he provided leadership for biotechnology, endocrine research and product development. He currently serves as a co-founder and board member of the biotechnology companies Ambrx, and Inproteo. He previously served as a board member of the biotechnology trade group BIO, and Millennium Biotherapeutics. Dr. DiMarchi�s current scientific activities remain focused on the relationship of protein structure and function, with a particular interest in novel methods of macromolecular synthesis and drug delivery. He contributed appreciably to the discovery of Humalog� and commercial development of Humulin�, Humatrope�, Glucagon�, Xigris�, Forteo�, and Evista�. Humalog represents the first biosynthetic hormone optimized by rDNA technology approved as a human medicine and presently registers annual sales in excess of one billon US dollars. He is a leading proponent for the integration of new technologies and approaches to pharmaceutical R&D and an ardent proponent of molecular diversity. Dr. DiMarchi received his Ph.D. in Biochemistry from Indiana University. | 